Research Study

Multicenter, Double Blind, Placebo Controlled Study of Vonapanitase (PRT- 201) Administered Immediately After Radiocephalic Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease
Principal Investigator 
Jerry C.L. Chen

Overview

Body Locations and Systems 
Kidney Disease
ClinicalTrials.gov# 
NCT02414841
Status 
Recruiting
Study Start/End 
May 1, 2016 to May 4, 2017
Locations 
Diamond Health Care Centre, Vancouver General Hospital
Name/Title 
Rory-Lynn Cunada, Research Nurse
Phone 
604-875-5077
Purpose of Study 

This research study is designed to assess the safety and effectiveness of an experimental drug called vonapanitase (PRT-201) in patients who have chronic kidney disease and who are undergoing surgery to create a new access point to their bloodstream for hemodialysis. Vonapanitase is a protein that has been shown in previous research studies to help keep vessels patent when applied to the outside surface of the blood vessels (arteries and veins) in patients who undergo surgery to create an arteriovenous fistula (AVF). The purpose of this study is to determine whether vonapanitase when applied to a limited segment of your blood vessel (about 2 inches) immediately after surgery is safe and improves the patency of your AVF.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.